title: Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation.
abstract: BACKGROUND
  A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx).
  
  
  METHODS
  Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n = 20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n = 10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively.
  
  
  RESULTS
  Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, -92 to -34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%-97%) were steroid free.
  
  
  CONCLUSIONS
  These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx.
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore. grmvat@sgh.com.sg
authors.forename: Anantharaman
authors.initials: A
authors.lastname: Vathsala
authors.forename: Enrique T
authors.initials: ET
authors.lastname: Ona
authors.forename: Si-Yen
authors.initials: SY
authors.lastname: Tan
authors.forename: Shirley
authors.initials: S
authors.lastname: Suresh
authors.forename: Huei-Xin
authors.initials: HX
authors.lastname: Lou
authors.forename: Concesa B Cabanayan
authors.initials: CB
authors.lastname: Casasola
authors.forename: Hung-Chew
authors.initials: HC
authors.lastname: Wong
authors.forename: David
authors.initials: D
authors.lastname: Machin
authors.forename: Gilbert S C
authors.initials: GS
authors.lastname: Chiang
authors.forename: Romina A
authors.initials: RA
authors.lastname: Danguilan
authors.forename: Roy
authors.initials: R
authors.lastname: Calne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000494:pharmacology*; D016572:Cyclosporine / Q000493:pharmacokinetics; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007167:Immunotherapy; D007668:Kidney / Q000187:drug effects* / Q000276:immunology / Q000502:physiology*; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D016572:Cyclosporine